Akebia Therapeutics (AKBA)

• Market cap: $251M
• 1 day: -3.61%
• 5 days: -9.19%
• 1 month: -35.5%
• 3 months: -21.4%
• 6 months: -39.27%
• Year to date: -39.66%
• 1 year: -74.65%
• 5 years: -72.81%
• 10 years: -89.32%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Employees: 194